Active surveillance in management of younger men with prostate cancer

Your sitemaster has long argued that it is perfectly reasonable for many younger men diagnosed with low- and very low-risk forms of prostate cancer to be managed initially on active surveillance (despite reticence on the parts of many physicians and many patients). … READ MORE …

Age, active surveillance, and age-related risk for progression

A new report in the Journal of Clinical Oncology suggests that younger patients had a somewhat lower risk for biopsy-based Gleason score upgrade while on active surveillance (AS) than older patients. … READ MORE …

Clinician characteristics affect likelihood of PSA testing in older men

A new article in JAMA Internal Medicine has quantified (to some extent) how characteristics of clinicians affect the probability of older men being given PSA tests within the Veterans Administration health system here in the US. … READ MORE …

A duty of care in the management of prostate cancer

A new article in the journal Nature Reviews: Urology is entitled, “The implications of ageing and life expectancy in prostate cancer treatment.” It’s an important issue. … READ MORE …

How good is your relationship with your son or sons?

And in today’s exciting news comes something that it is too late for most prostate cancer patients to do anything about personally (and which they can complain about if they did and they still got prostate cancer … although we’re not sure to whom)! … READ MORE …

PSA testing among black males here in America

It is well understood that African-American men and other “black” males of African ethnic origin are at greater risk for prostate cancer (at least here in America) than are non-Hispanic “white” males. What has been less clear is whether such black males are conscious of that risk and take appropriate action. … READ MORE …

The biology and pathology of “young age” prostate cancer

A recent article in the Journal of Clinical Pathology reviews available data about the epidemiology, biology, and clinical pathology of “young age” prostate cancer, which the authors define as clinically significant cancer in men under 55 years of age. … READ MORE …